主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
RZLT
#2756
Rezolute, Inc. Common Stock (NV)
3.2
1
-1.53%
版块:
基础:
利润货币:
日范围
年范围
日变化
-1.53%
每月变动
-8.29%
6个月变化
-55.72%
年变化
-24.47%
前一天收盘价
3.2
6
Open
3.2
1
Bid
Ask
Low
3.2
1
High
3.2
1
交易量
66
市场
股票
医疗保健
RZLT
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
TTM
Key stats
Total common shares outstanding
85.52 M
90.81 M
92.73 M
95.7 M
—
Valuation ratios
Enterprise value
233.41 M
310.91 M
862.54 M
213.95 M
1.62 B
Price to earnings ratio
6.61
-4.55
17.64
62.92
82.62
Price to sales ratio
74.42
—
16.78 K
7 456.56
—
Price to cash flow ratio
2.44
4.91
9.19
2.35
18.88
Price to book ratio
0.38
2.09
1.35
0.36
4.19
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
0.2
0.14
0.11
0.16
0.62
Return on equity %
0.23
0.15
0.12
0.18
0.68
Return on invested capital %
—
-618.92
—
—
—
Gross margin %
100
—
100
—
—
Operating margin %
333.72 K
—
132.11 K
—
—
EBITDA margin %
—
—
—
—
—
Net margin %
314.87 K
—
121.33 K
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
8.43
14.37
15.15
14.18
52.13
Inventory turnover
—
—
—
—
—
Asset turnover
0
—
0
0
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.29
0.29
0.19
0.22
0.99
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
1.44
2.21
1.7
1.42
6.77
Net current asset value per share
1.47
2.25
1.73
1.45
6.89
Tangible book value per share
1.18
2.13
1.42
1.23
5.97
Working capital per share
1.29
2.1
1.61
1.35
6.34
Book value per share
1.36
2.13
1.64
1.37
6.51
新闻
Alger Small Cap Growth Fund Q4 2025 Portfolio Update
Jefferies重申Rezolute股票买入评级,维持4美元目标价
Jefferies reiterates Buy rating on Rezolute stock, maintains $4 target
Rezolute公司罕见疾病疗法三期临床试验结果喜忧参半
Rezolute shares mixed results from Phase 3 trial for rare disease therapy
Leerink Partners维持XOMA股票"跑赢大盘"评级,目标价45美元
Leerink Partners reiterates Outperform rating on XOMA stock at $45 target
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
Rezolute首席财务官Evans购买价值$79,577的股票
Rezolute CFO Evans buys shares worth $79,577
Rezolute公司CEO Elam Nevan C.购入价值5万美元的RZLT股票
Elam Nevan C, Rezolute CEO, buys $50k in RZLT shares